Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Findings from University of North Dakota broaden understanding of breast cancer
January 6th, 2009
According to recent research from the United States, "While increased urokinase-type plasminogen activator (uPA) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that uPA overexpression may suppress tumor growth and prolong survival. Celecoxib has been shown to have antiangiogenic and antiproliferative properties." "We sought to determine if uPA, PA inhibitor (PAI)-1 and prostaglandin (PG) E-2 expression in nipple aspirate fluid (NAF) and uPA and PGE(2) expression in plasma were altered by celecoxib dose and concentration in women at increased breast cancer risk. NAF and plasma samples were collected in women at...
Source: Cancer Weekly (2009-01-06)
|
